Arata Azuma
- Macrolide effects on the prevention of COPD exacerbationsBy Mutsuo Yamaya, Arata Azuma, Hajime Takizawa, Jun-ichi Kadota, Jun Tamaoki and Shoji KudohMutsuo Yamaya*Dept of Advanced Preventive Medicine for Infectious Disease, Tohoku University Graduate School of Medicine, SendaiArata Azuma#Division of Pulmonary Medicine, Infectious Diseases and Oncology, Dept of Internal Medicine, Nippon Medical SchoolHajime Takizawa¶Dept of Respiratory Medicine, Kyorin University HospitalJun-ichi Kadota+Internal Medicine II, Oita University Faculty of Medicine, Oita, JapanJun Tamaoki§First Dept of Medicine, Tokyo Women's Medical CollegeShoji KudohfFukujuji Hospital, Japan Tuberculosis Association, Tokyo
- Genetic analysis of two novel mucin-like genes in the disease-susceptibility locus for diffuse panbronchiolitisBy Minako Hijikata, Ikumi Matsushita, Hideyuki Ito, Jun Ohashi, Sakae Homma, Yoshio Taguchi, Arata Azuma, Shoji Kudoh and Naoto KeichoMinako Hijikata1Department of Respiratory Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, JapanIkumi Matsushita1Department of Respiratory Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, JapanHideyuki Ito2Department of Thoracic Surgery, National Center for Global Health and Medicine, Tokyo, JapanJun Ohashi3Department of Public Health Medicine, University of Tsukuba, Ibaraki, JapanSakae Homma4Department of Respiratory Medicine, Toho University School of Medicine, Tokyo, JapanYoshio Taguchi5Department of Respiratory Medicine, Tenri Hospital, Nara, JapanArata Azuma6Division of Pulmonary Medicine, Nippon Medical School, Tokyo, JapanShoji Kudoh7President, Fukujuji Hospital, Tokyo, JapanNaoto Keicho1Department of Respiratory Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan
- Disruption of Nrf2 enhances susceptibility to pulmonary fibrosis induced by bleomycin in miceBy Ying-Ji Li, Takako Shimizu, Yukiyo Hirata, Hirofumi Inagaki, Arata Azuma, Hajime Takizawa, Satoru Takahashi, Masayuki Yamamoto, Tomoyuki Kawada and Shoji KudohYing-Ji Li1Department of Hygiene and Public Health, Nippon Medical School, Tokyo, JapanTakako Shimizu1Department of Hygiene and Public Health, Nippon Medical School, Tokyo, JapanYukiyo Hirata1Department of Hygiene and Public Health, Nippon Medical School, Tokyo, JapanHirofumi Inagaki1Department of Hygiene and Public Health, Nippon Medical School, Tokyo, JapanArata Azuma2Department of Pulmonary Medicine/Infection and Oncology, Nippon Medical School, Tokyo, JapanHajime Takizawa3Fourth Department of Internal Medicine, Teikyo University, School of Medicine, Kawasaki, JapanSatoru Takahashi4Department of Anatomy and Embryology,Biomolecular and Integrated Medical Sciences, University of Tsukuba, Ibaragi, JapanMasayuki Yamamoto5Department of Biochemistry, Tohoku University Graduate School of Medicine, Sendai, JapanTomoyuki Kawada1Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan
- Risk factors of acute exacerbation of idiopathic pulmonary fibrosis-extended analysis of the pirfenidone trial in JapanBy Hiroyuki Taniguchi, Yasuhiro Kondoh, Masahito Ebina, Arata Azuma, Takashi Ogura, Moritaka Suga, Yoshio Taguchi, Hiroki Takahashi, Koichiro Nakata, Atuhiko Sato, Yukihiko Sugiyama, Shoji Kudoh and Toshihiro NukiwaHiroyuki Taniguchi1Dept. of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Aichi, JapanYasuhiro Kondoh1Dept. of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Aichi, JapanMasahito Ebina2Dept. of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, JapanArata Azuma3Dept. of Internal Medicine, Nippon Medical School, Tokyo, JapanTakashi Ogura4Dept. of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, JapanMoritaka Suga5Dept. of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, JapanYoshio Taguchi6Dept. of Respiratory Medicine, Tenri Hospital, Tenri, JapanHiroki Takahashi7Third Dept. of Internal Medicine, Sapporo Medical University of Medicine, Sapporo, JapanKoichiro Nakata8Dept. of Respiratory Medicine, Nakata Clinic, Tokyo, JapanAtuhiko Sato9Dept. of Respiratory Medicine, Medicine Kyoto Preventive, Kyoto, JapanYukihiko Sugiyama10Division of Pulmonary Medicine, Dept. of Medicine, Jichi Medical University, Tochigi, JapanShoji Kudoh3Dept. of Internal Medicine, Nippon Medical School, Tokyo, JapanToshihiro Nukiwa2Dept. of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
- Interstitial lung disease associated by gemcitabine chemotherapy in non-small lung cancer patients: Analysis based on the data in practical use with confirmed denominatorBy Yukiko Miura, Yoshinobu Saito, Yuji Minegishi, Arata Azuma and Akihiko GemmaYukiko MiuraInternal Medicine, Division of Pulmonary Medicine Infection and Oncology, Nippon Medical School, Tokyo, JapanYoshinobu SaitoInternal Medicine, Division of Pulmonary Medicine Infection and Oncology, Nippon Medical School, Tokyo, JapanYuji MinegishiInternal Medicine, Division of Pulmonary Medicine Infection and Oncology, Nippon Medical School, Tokyo, JapanArata AzumaInternal Medicine, Division of Pulmonary Medicine Infection and Oncology, Nippon Medical School, Tokyo, JapanAkihiko GemmaInternal Medicine, Division of Pulmonary Medicine Infection and Oncology, Nippon Medical School, Tokyo, Japan
- Effect of baseline FVC on preservation of lung function with BIBF 1120: Results from the TOMORROW trialBy Luca Richeldi, Ulrich Costabel, Moises Selman, Dong Soon Kim, Kevin R. Flaherty, Paul W. Noble, Ganesh Raghu, Arata Azuma, Michèle Brun, Abhya Gupta, Matthias Klueglich, Nolwenn Juhel and Roland M. du BoisLuca Richeldi1Center for Rare Luna Disease, University of Modena and Reggio Emilia, Modena, ItalyUlrich Costabel2Ruhrlandklinik and Medical Faculty, University of Duisburg-Essen, Essen, GermanyMoises Selman3Instituto Nacional de Enfermedades Respiratorias, “Ismael Cosio Villegas”, Mèxico, MexicoDong Soon Kim4Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan, Seoul, KoreaKevin R. Flaherty5Department of Internal Medicine, Pulmonary and Critical Care Division, University of Michigan, Ann Arbor, United StatesPaul W. Noble6Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, United StatesGanesh Raghu7Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, United StatesArata Azuma8Division of Respiratory Medicine, Infection and Oncology, Nippon Medical School, Tokyo, JapanMichèle Brun9Boehringer Ingelheim France S.A.S., Boehringer Ingelheim, Reims, FranceAbhya Gupta10Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim, Biberach, GermanyMatthias Klueglich10Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim, Biberach, GermanyNolwenn Juhel9Boehringer Ingelheim France S.A.S., Boehringer Ingelheim, Reims, FranceRoland M. du Bois11National Heart & Lung Institute, Imperial College, London, United Kingdom
- Late-breaking abstract: Pathological analysis of acute exacerbation of idiopathic pulmonary fibrosis (IPF)By Yuh Fukuda, Mika Terasaki, Mikiko Takahashi, Shinobu Kunugi, Yasuhiro Terasaki, Hirokazu Urushiyama and Arata AzumaYuh Fukuda1Department of Analytic Human Pathology, Nippon Medical School, Bunkyo-ku, Tokyo, JapanMika Terasaki1Department of Analytic Human Pathology, Nippon Medical School, Bunkyo-ku, Tokyo, JapanMikiko Takahashi1Department of Analytic Human Pathology, Nippon Medical School, Bunkyo-ku, Tokyo, JapanShinobu Kunugi1Department of Analytic Human Pathology, Nippon Medical School, Bunkyo-ku, Tokyo, JapanYasuhiro Terasaki1Department of Analytic Human Pathology, Nippon Medical School, Bunkyo-ku, Tokyo, JapanHirokazu Urushiyama1Department of Analytic Human Pathology, Nippon Medical School, Bunkyo-ku, Tokyo, JapanArata Azuma2Department of Pulmonary, Infection and Oncology, Nippon Medical School, Bunkyo-ku, Tokyo, Japan
- Promising effect of PMX-DHP absorption therapy for acute exacerbation of IPFBy Arata Azuma, Shinji Abe, Takashi Ogura, Hiroshi Mukae, Hiroyuki Taniguchi, Masashi Bando and Yukihiko SugiyamaArata Azuma1Division of Respiratory Medicine, Infection and Oncology, Nippon Medical School, Tokyo, JapanShinji Abe1Division of Respiratory Medicine, Infection and Oncology, Nippon Medical School, Tokyo, JapanTakashi Ogura2Respiratory Medicine, Kanagawa Cardiovascuiar and Respiratory Center, Yokohama, Kanagawa, JapanHiroshi Mukae3Department of Respiratory Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, JapanHiroyuki Taniguchi4Division of Respiratory Medicine, Allergic Internal Medicine, Tosei General Hospital, Seto, Aichi, JapanMasashi Bando5Department of Pulmonary Medicine, Jichi Medical University, Shimotsuke, Tochigi, JapanYukihiko Sugiyama5Department of Pulmonary Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan
- The efficacy of pirfenidone in scleroderma related interstitial lung diseaseBy Yukiko Miura, Yoshiya Tsunoda, Toru Tanaka, Hiroyuki Takoi, Yohei Yatagai, Shigen Rin, Akimasa Sekine, Kenji Hayashihara, Takefumi Saito, Akihiko Gemma and Arata AzumaYukiko Miura1Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Ibaraki, JapanYoshiya Tsunoda1Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Ibaraki, JapanToru Tanaka1Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Ibaraki, JapanHiroyuki Takoi1Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Ibaraki, JapanYohei Yatagai1Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Ibaraki, JapanShigen Rin1Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Ibaraki, JapanAkimasa Sekine1Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Ibaraki, JapanKenji Hayashihara1Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Ibaraki, JapanTakefumi Saito1Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Ibaraki, JapanAkihiko Gemma2Division of Pulmonary Medicine, Infection and Oncology, Nippon Medical School, Internal Medicine, Tokyo, JapanArata Azuma2Division of Pulmonary Medicine, Infection and Oncology, Nippon Medical School, Internal Medicine, Tokyo, Japan
- Nrf2 is closely related to enhance bleomycin induced airway inflammatory responses caused by diesel exhaust particles in miceBy Ying-Ji Li, Tkako Shimizu, Yukiyo Hirata, Hirofumi Inagaki, Yusuke Shinkai, Ken Takeda, Arata Azuma, Hajime Takizawa, Yamamoto Masayuki, Tomoyuki Kawada and Shoji KudohYing-Ji Li1Hygiene and Public Health, Nippon Medical School, Tokyo, JapanTkako Shimizu1Hygiene and Public Health, Nippon Medical School, Tokyo, JapanYukiyo Hirata1Hygiene and Public Health, Nippon Medical School, Tokyo, JapanHirofumi Inagaki1Hygiene and Public Health, Nippon Medical School, Tokyo, JapanYusuke Shinkai2Hygiene Chemistry, Faculty of Pharmaceutical Sciences, Tokyo University of Sciences, Noda, JapanKen Takeda2Hygiene Chemistry, Faculty of Pharmaceutical Sciences, Tokyo University of Sciences, Noda, JapanArata Azuma3Pulmonary Medicine/Infection and Oncology, Nippon Medical School, Tokyo, JapanHajime Takizawa4Pulmonary Medicine, Kyorin University, School of Medicine, Mitaka, JapanYamamoto Masayuki5Biochemistry, Tohoku University Graduate School of Medicine, Sendai, JapanTomoyuki Kawada1Hygiene and Public Health, Nippon Medical School, Tokyo, JapanShoji Kudoh6Fukujuji Hospital, Anti-Tuberculosis Association, Kiyose, Japan
- Clinico-pathological analysis of acute respiratory distress syndrome (ARDS)By Yuh Fukuda, Mikiko Takahashi, Shinobu Kunugi, Mika Terasaki, Hirokazu Urushiyama, Yasuhiro Terasaki and Arata AzumaYuh Fukuda1Department of Analytic Human Pathology, Nippon Medical School, Sendagi Bunkyo-ku, Tokyo, JapanMikiko Takahashi1Department of Analytic Human Pathology, Nippon Medical School, Sendagi Bunkyo-ku, Tokyo, JapanShinobu Kunugi1Department of Analytic Human Pathology, Nippon Medical School, Sendagi Bunkyo-ku, Tokyo, JapanMika Terasaki1Department of Analytic Human Pathology, Nippon Medical School, Sendagi Bunkyo-ku, Tokyo, JapanHirokazu Urushiyama1Department of Analytic Human Pathology, Nippon Medical School, Sendagi Bunkyo-ku, Tokyo, JapanYasuhiro Terasaki1Department of Analytic Human Pathology, Nippon Medical School, Sendagi Bunkyo-ku, Tokyo, JapanArata Azuma2Department of Pulmonary, Infection and Oncology, Nippon Medical School, Sendagi Bunkyo-ku, Tokyo, Japan
- Diesel exhaust particle induce epithelial-to-mesenchymal transition by oxidative stress in human bronchial epithelial cellBy Ying-Ji Li, Takako Shimizu, Yukiyo Hirata, Hirofumi Inagaki, Yusuke Shinkai, Ken Takeda, Arata Azuma, Hajime Takizawa, Xiangde Liu, Tomoyuki Kawada and Shoji KudohYing-Ji Li1Department of Hygiene and Public Health, Nippon Medical School, Tokyo, JapanTakako Shimizu1Department of Hygiene and Public Health, Nippon Medical School, Tokyo, JapanYukiyo Hirata1Department of Hygiene and Public Health, Nippon Medical School, Tokyo, JapanHirofumi Inagaki1Department of Hygiene and Public Health, Nippon Medical School, Tokyo, JapanYusuke Shinkai2Hygiene Chemistry, Faculty of Pharmaceutical Sciences, Tokyo University of Sciences, Noda, JapanKen Takeda2Hygiene Chemistry, Faculty of Pharmaceutical Sciences, Tokyo University of Sciences, Noda, JapanArata Azuma3Department of Pulmonary Medicine/Infection and Oncology, Nippon Medical School, Tokyo, JapanHajime Takizawa4Department of Respiratory Medicine, Kyorin University Hospital, Tokyo, JapanXiangde Liu5Department of Pulmonary, Critical Care, and Sleep Medicine, University of Nebraska Medical Center, Omaha, United StatesTomoyuki Kawada1Department of Hygiene and Public Health, Nippon Medical School, Tokyo, JapanShoji Kudoh3Department of Pulmonary Medicine/Infection and Oncology, Nippon Medical School, Tokyo, Japan6Department of Respiratory Medicine, Anti-Tuberculosis Association, Fukujuji Hospital, Tokyo, Japan
- Macrolide effects on the prevention of COPD exacerbationsBy Mutsuo Yamaya, Arata Azuma, Hajime Takizawa, Jun-ichi Kadota, Jun Tamaoki and Shoji KudohArticle | Published in 2012 in European Respiratory JournalMutsuo YamayaArata AzumaHajime TakizawaJun-ichi KadotaJun Tamaoki
- Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosisBy Takashi Ogura, Hiroyuki Taniguchi, Arata Azuma, Yoshikazu Inoue, Yasuhiro Kondoh, Yoshinori Hasegawa, Masashi Bando, Shinji Abe, Yoshiro Mochizuki, Kingo Chida, Matthias Klüglich, Tsuyoshi Fujimoto, Kotaro Okazaki, Yusuke Tadayasu, Wataru Sakamoto and Yukihiko SugiyamaArticle | Published in 2014 in European Respiratory JournalTakashi Ogura1Dept of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, JapanHiroyuki Taniguchi2Dept of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, JapanArata Azuma3Graduate School of Medicine Nippon Medical School, Tokyo, JapanYoshikazu Inoue4Dept of Diffuse Lung Diseases and Respiratory Failure, Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, JapanYasuhiro Kondoh2Dept of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, JapanYoshinori Hasegawa5Dept of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, JapanMasashi Bando6Division of Pulmonary Medicine, Dept of Medicine, Jichi Medical University, Tochigi, JapanShinji Abe3Graduate School of Medicine Nippon Medical School, Tokyo, JapanYoshiro Mochizuki7Respiratory Medicine, Himeji Medical Center, Himeji, JapanKingo Chida8Second Division, Dept of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, JapanMatthias Klüglich9Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, GermanyTsuyoshi Fujimoto10Nippon Boehringer Ingelheim Co. Ltd, Tokyo, JapanKotaro Okazaki10Nippon Boehringer Ingelheim Co. Ltd, Tokyo, JapanYusuke Tadayasu10Nippon Boehringer Ingelheim Co. Ltd, Tokyo, JapanWataru Sakamoto10Nippon Boehringer Ingelheim Co. Ltd, Tokyo, JapanYukihiko Sugiyama6Division of Pulmonary Medicine, Dept of Medicine, Jichi Medical University, Tochigi, Japan
- Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosisBy Takashi Ogura, Hiroyuki Taniguchi, Arata Azuma, Yoshikazu Inoue, Yasuhiro Kondoh, Yoshinori Hasegawa, Masashi Bando, Shinji Abe, Yoshiro Mochizuki, Kingo Chida, Matthias Klüglich, Tsuyoshi Fujimoto, Kotaro Okazaki, Yusuke Tadayasu, Wataru Sakamoto and Yukihiko SugiyamaArticle | Published in 2014 in European Respiratory JournalTakashi Ogura1Dept of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, JapanHiroyuki Taniguchi2Dept of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, JapanArata Azuma3Graduate School of Medicine Nippon Medical School, Tokyo, JapanYoshikazu Inoue4Dept of Diffuse Lung Diseases and Respiratory Failure, Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, JapanYasuhiro Kondoh2Dept of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, JapanYoshinori Hasegawa5Dept of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, JapanMasashi Bando6Division of Pulmonary Medicine, Dept of Medicine, Jichi Medical University, Tochigi, JapanShinji Abe3Graduate School of Medicine Nippon Medical School, Tokyo, JapanYoshiro Mochizuki7Respiratory Medicine, Himeji Medical Center, Himeji, JapanKingo Chida8Second Division, Dept of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, JapanMatthias Klüglich9Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, GermanyTsuyoshi Fujimoto10Nippon Boehringer Ingelheim Co. Ltd, Tokyo, JapanKotaro Okazaki10Nippon Boehringer Ingelheim Co. Ltd, Tokyo, JapanYusuke Tadayasu10Nippon Boehringer Ingelheim Co. Ltd, Tokyo, JapanWataru Sakamoto10Nippon Boehringer Ingelheim Co. Ltd, Tokyo, JapanYukihiko Sugiyama6Division of Pulmonary Medicine, Dept of Medicine, Jichi Medical University, Tochigi, Japan
- Effect of baseline FVC on decline in lung function with nintedanib: Results from the INPULSIS™ trialsBy Ulrich Costabel, Yoshikazu Inoue, Luca Richeldi, Harold R. Collard, Susanne Stowasser, Inga Tschoepe and Arata AzumaUlrich Costabel1Ruhrlandklinik, University Hospital, University of Duisburg-Essen, Essen, GermanyYoshikazu Inoue2Department of Diffuse Lung Diseases and Respiratory Failure, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, JapanLuca Richeldi3Faculty of Medicine, University of Southampton, Southampton, United KingdomHarold R. Collard4Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA,Susanne Stowasser5Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanyInga Tschoepe6Statistics, Boehringer Ingelheim France S.A.S., Reims, FranceArata Azuma7Division of Respiratory Medicine, Infection and Oncology, Nippon Medical School, Tokyo, Japan
- Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidoneBy Hiroyuki Taniguchi, Arata Azuma, Takashi Ogura, Yoshikazu Inoue, Kingo Chida, Masashi Bando, Shinichi Kakutani, Shuichiro Inagaki, Moritaka Suga, Yukihiko Sugiyama, Shoji Kudoh and Toshihiro NukiwaHiroyuki Taniguchi1Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Aichi, JapanArata Azuma2Department of Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, JapanTakashi Ogura3Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, JapanYoshikazu Inoue4Department of Diffuse Lung Diseases and Respiratory Failure, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Osaka, JapanKingo Chida5Department of Respiratory Medicine, Hamamatsu Toyooka Hospital, Hamamatsu, Shizuoka, JapanMasashi Bando6Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, JapanShinichi Kakutani7Center for Statistics and Analysis, Shionogi & Co., Ltd, Osaka, JapanShuichiro Inagaki7Center for Statistics and Analysis, Shionogi & Co., Ltd, Osaka, JapanMoritaka Suga8Center for Preventive Medicine, Saiseikai Kumamoto Hospital, Kumamoto, JapanYukihiko Sugiyama6Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, JapanShoji Kudoh9Department of Respiratory Medicine, Fukujuji Hospital, Kiyose, Tokyo, JapanToshihiro Nukiwa10Department of Respiratory Medicine, South Miyagi Medical Center, Shibata, Miyagi, Japan
- Pirfenidone post-authorization safety registry (PASSPORT) – Interim analysis of IPF treatmentBy Dirk Koschel, Vincent Cottin, Magnus Skold, Sara Tomassetti, Arata Azuma, Christophe Giot, David Yocum, Sundos Hamza and Toby M. MaherDirk Koschel1Respiratory Medicine, Fachkrankenhaus Coswig, Coswig, Saxony, GermanyVincent Cottin2Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Lyon 1 University, Lyon, FranceMagnus Skold3Medicine Solna, Karolinska Institutet, Stockholm, SwedenSara Tomassetti4Diseases of the Thorax, GB Morgagni Hospital, Forli, FC, ItalyArata Azuma5Post-graduate School of Medicine, Pulmonary Medicine, Nippon Medical School, Tokyo, JapanChristophe Giot6Medical Sciences EU, InterMune, Inc., Muttenz, BL, SwitzerlandDavid Yocum7Drug Safety Risk Management, InterMune, Inc., Brisbane, CA,Sundos Hamza7Drug Safety Risk Management, InterMune, Inc., Brisbane, CA,Toby M. Maher8Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United Kingdom
- Clinical effect of pirfenidone on incidence of lung carcinoma in chronic interstitial pneumoniaBy Yukiko Miura, Takefumi Saito, Yoshiya Tsunoda, Toru Tanaka, Hiroyuki Takoi, Yohei Yatagai, Shih-Yuan Lin, Akimasa Sekine, Kenji Hayashihara, Minoru Inomata, Takahito Nei, Yoshinobu Saito, Akihiko Gemma and Arata AzumaYukiko Miura1Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Ibaraki, JapanTakefumi Saito1Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Ibaraki, JapanYoshiya Tsunoda1Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Ibaraki, JapanToru Tanaka1Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Ibaraki, JapanHiroyuki Takoi1Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Ibaraki, JapanYohei Yatagai1Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Ibaraki, JapanShih-Yuan Lin1Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Ibaraki, JapanAkimasa Sekine1Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Ibaraki, JapanKenji Hayashihara1Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Ibaraki, JapanMinoru Inomata2Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, JapanTakahito Nei2Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, JapanYoshinobu Saito2Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, JapanAkihiko Gemma2Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, JapanArata Azuma2Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
- Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosisBy Takashi Ogura, Hiroyuki Taniguchi, Arata Azuma, Yoshikazu Inoue, Yasuhiro Kondoh, Yoshinori Hasegawa, Masashi Bando, Shinji Abe, Yoshiro Mochizuki, Kingo Chida, Matthias Klüglich, Tsuyoshi Fujimoto, Kotaro Okazaki, Yusuke Tadayasu, Wataru Sakamoto and Yukihiko SugiyamaTakashi Ogura1Dept of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, JapanHiroyuki Taniguchi2Dept of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, JapanArata Azuma3Graduate School of Medicine Nippon Medical School, Tokyo, JapanYoshikazu Inoue4Dept of Diffuse Lung Diseases and Respiratory Failure, Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, JapanYasuhiro Kondoh2Dept of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, JapanYoshinori Hasegawa5Dept of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, JapanMasashi Bando6Division of Pulmonary Medicine, Dept of Medicine, Jichi Medical University, Tochigi, JapanShinji Abe3Graduate School of Medicine Nippon Medical School, Tokyo, JapanYoshiro Mochizuki7Respiratory Medicine, Himeji Medical Center, Himeji, JapanKingo Chida8Second Division, Dept of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, JapanMatthias Klüglich9Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, GermanyTsuyoshi Fujimoto10Nippon Boehringer Ingelheim Co. Ltd, Tokyo, JapanKotaro Okazaki10Nippon Boehringer Ingelheim Co. Ltd, Tokyo, JapanYusuke Tadayasu10Nippon Boehringer Ingelheim Co. Ltd, Tokyo, JapanWataru Sakamoto10Nippon Boehringer Ingelheim Co. Ltd, Tokyo, JapanYukihiko Sugiyama6Division of Pulmonary Medicine, Dept of Medicine, Jichi Medical University, Tochigi, Japan
- Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumoniaBy Minoru Inomata, Yukiko Miura, Nariaki Kokuho, Hiroki Hayashi, Takahito Nei, Koichiro Kamio, Kazue Fujita, Yoshinobu Saito, Akihiko Gemma, Takefumi Saito and Arata AzumaMinoru Inomata1Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, JapanYukiko Miura1Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, JapanNariaki Kokuho1Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, JapanHiroki Hayashi1Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, JapanTakahito Nei1Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, JapanKoichiro Kamio1Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, JapanKazue Fujita1Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, JapanYoshinobu Saito1Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, JapanAkihiko Gemma1Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, JapanTakefumi Saito2Department of Respiratory Medicine, Ibaraki-Higashi National Hospital, Ibaraki, JapanArata Azuma1Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
- Pirfenidone post-authorization safety registry (PASSPORT) updateBy Vincent Cottin, Toby M. Maher, Arata Azuma, Lesley Groves, Philip Hormel, Magnus Sköld, Sara Tomassetti and Dirk KoschelVincent Cottin1Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Lyon University, Lyon, FranceToby M. Maher2Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United KingdomArata Azuma3Post-Graduate School of Medicine, Pulmonary Medicine, Nippon Medical School, Tokyo, JapanLesley Groves4Intermune/Roche, Intermune/Roche, Brisbane, CA United StatesPhilip Hormel4Intermune/Roche, Intermune/Roche, Brisbane, CA United StatesMagnus Sköld5Medicine Solna, Karolinska Institutet, Stockholm, SwedenSara Tomassetti6Diseases of the Thorax, GB Morgagni Hospital, Forli, FC ItalyDirk Koschel7Respiratory Medicine, Fachkrankenhaus Coswig, Coswig, Saxony Germany
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.